Suppr超能文献

一项随机、开放标签、五交叉研究,旨在评估健康志愿者中呋塞米与非甾体抗炎药双氯芬酸和布洛芬之间的药代动力学/药效学相互作用。

Randomized, open-label, 5-way crossover study to evaluate the pharmacokinetic/pharmacodynamic interaction between furosemide and the non-steroidal anti-inflammatory drugs diclofenac and ibuprofen in healthy volunteers.

作者信息

Paterson C A, Jacobs D, Rasmussen S, Youngberg S P, McGuinness N

机构信息

Pfizer, Inc., Cary, NC, USA.

出版信息

Int J Clin Pharmacol Ther. 2011 Aug;49(8):477-90. doi: 10.5414/cp201492.

Abstract

OBJECTIVE

Nonsteroidal anti-inflammatory drugs (NSAIDs) can induce renal complications in patients taking loop diuretics. This study investigated the pharmacokinetic/pharmacodynamic effects and safety profile of orally administered diclofenac sodium, ibuprofen and diclofenac epolamine topical patch (DETP) on furosemide in healthy adult subjects.

METHODS

This open-label, randomized, 5-way crossover study was conducted in 40 subjects (aged 19 - 45 y). Diclofenac (75 mg taken orally twice daily), DETP (1.3% applied topically twice daily), or ibuprofen (800 mg taken orally thrice daily) was administered for 3 consecutive days, followed by co-administration with furosemide (given intravenously as 20 mg/2 min). Plasma furosemide and NSAID concentrations, urine furosemide, sodium and potassium concentrations and urine output were determined throughout the 24 h period following furosemide administration.

RESULTS

Orally administered ibuprofen significantly increased furosemide AUC(0-t) (37%) and AUC(0-inf) (36%) and decreased total body CL (27%), R(max) (19%) and CLR (23%) geometric mean ratios compared with furosemide control. Oral and topical diclofenac had no pharmacokinetic effects on furosemide. Ibuprofen increased sodium excretion (Ae(0-24), 16%) and decreased sodium R(max) (15%), and oral diclofenac decreased urine output (Vu(0-24), 15%). DETP had no effect on furosemide pharmacodynamics; total systemic exposure to diclofenac during DETP treatment was < 1% that of oral diclofenac. Treatments were generally safe, with 25 subjects reporting a total of 112 adverse events.

CONCLUSIONS

Pharmacodynamic effects were seen with oral diclofenac (urine output) and ibuprofen (urine sodium excretion). Furosemide also affected plasma and urine pharmacokinetic profiles. Pharmacologic effects of DETP on furosemide were not observed under these conditions. Additional research is warranted to delineate the potential interactions of other NSAIDs with furosemide and other loop diuretics.

摘要

目的

非甾体抗炎药(NSAIDs)可在服用袢利尿剂的患者中诱发肾脏并发症。本研究调查了口服双氯芬酸钠、布洛芬和双氯芬酸依泊胺贴剂(DETP)对健康成年受试者体内呋塞米的药代动力学/药效学作用及安全性。

方法

本开放标签、随机、五交叉研究纳入了40名受试者(年龄19 - 45岁)。连续3天给予双氯芬酸(每日口服2次,每次75 mg)、DETP(每日局部应用2次,每次1.3%)或布洛芬(每日口服3次,每次800 mg),随后与呋塞米(以20 mg/2 min静脉注射)联合给药。在呋塞米给药后的24小时内,测定血浆呋塞米和NSAIDs浓度、尿呋塞米、钠和钾浓度以及尿量。

结果

与呋塞米对照组相比,口服布洛芬显著增加了呋塞米的AUC(0 - t)(37%)和AUC(0 - inf)(36%),并降低了总体清除率(27%)、最大反应(19%)和肾清除率(23%)的几何平均比值。口服和局部应用双氯芬酸对呋塞米没有药代动力学影响。布洛芬增加了钠排泄(Ae(0 - 24),16%)并降低了钠最大反应(15%),口服双氯芬酸降低了尿量(Vu(0 - 24),15%)。DETP对呋塞米的药效学没有影响;DETP治疗期间双氯芬酸的全身总暴露量小于口服双氯芬酸的1%。治疗总体安全,25名受试者共报告了112起不良事件。

结论

口服双氯芬酸(尿量)和布洛芬(尿钠排泄)出现了药效学作用。呋塞米也影响了血浆和尿液药代动力学特征。在这些条件下未观察到DETP对呋塞米的药理作用。有必要进行更多研究以阐明其他NSAIDs与呋塞米及其他袢利尿剂之间的潜在相互作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验